Gilead Sciences Inc v. Cipla Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Gilead Sciences, Inc. (Delaware)
  • Defendant: Cipla Ltd. (India)
  • Plaintiff’s Counsel: Morris, Nichols, Arsht & Tunnell LLP; Wilmer Cutler Pickering Hale and Dorr LLP
• Case Identification: 1:26-cv-00149, D. Del., 02/10/2026
• Venue Allegations: Plaintiff alleges venue is proper because Defendant is a foreign corporation subject to personal jurisdiction in the district. Personal jurisdiction is alleged based on Defendant’s systematic contacts with Delaware, its intent to market the accused products in Delaware via a 505(b)(2) application, and its prior litigation conduct in the district, where it has previously availed itself of the court's jurisdiction.
• Core Dispute: Plaintiff alleges that Defendant’s planned generic version of the HIV drug DESCOVY® will infringe seven U.S. patents related to the active ingredient tenofovir alafenamide (TAF) and methods of its manufacture.
• Technical Context: The technology concerns specific salt forms and manufacturing processes for tenofovir alafenamide, an antiviral prodrug designed to improve the oral bioavailability and targeted delivery of tenofovir for the treatment of HIV.
• Key Procedural History: The complaint notes that Plaintiff and Defendant were previously involved in litigation over some of the same patents-in-suit ("the TAF ANDA Litigation"), which settled in 2022. This history may be relevant to allegations of knowledge for indirect infringement.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,754,065 - “Tenofovir Alafenamide Hemifumarate”

• Issued: June 17, 2014

The Invention Explained

• Problem Addressed: The complaint describes that while tenofovir is a potent HIV antiviral, it is not viable as an oral medicine Compl. ¶18 This necessitates the creation of "prodrugs"—modified molecules that are absorbed by the body and then convert to the active drug Compl. ¶18 A further challenge is creating a prodrug form that is stable, reproducible, and can be easily purified for pharmaceutical use U.S. Pat. No. 8,754,065, col. 5:1-10
• The Patented Solution: The patent discloses a specific salt form of the tenofovir prodrug TAF: tenofovir alafenamide hemifumarate (TAF Hemi) U.S. Pat. No. 8,754,065, abstract This form consists of two molecules of TAF associated with one molecule of fumaric acid Compl. ¶22 The complaint provides the chemical structure of the core TAF molecule Compl. ¶19 The patent explains this specific hemifumarate form provides advantages, including an "exceptional capability to purge" a major diastereomeric impurity, making it easier to manufacture a pure drug substance U.S. Pat. No. 8,754,065, col. 9:40-49
• Technical Importance: The creation of a stable, highly purifiable solid form of TAF was a key step in developing it into a commercially successful and widely used HIV medicine like DESCOVY® Compl. ¶¶2-3 U.S. Pat. No. 8,754,065, col. 5:1-10

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶49
• Claim 1 is a composition of matter claim defining a specific chemical entity. Its essential element is:
  • Tenofovir alafenamide hemifumarate

U.S. Patent No. 9,296,769 - “Tenofovir Alafenamide Hemifumarate”

• Issued: March 29, 2016

The Invention Explained

• Problem Addressed: As with the related ’065 Patent, this patent addresses the need for a stable and pure form of the TAF prodrug suitable for pharmaceutical use U.S. Pat. No. 9,296,769, col. 1:18-28 The background specifically notes that other forms, such as the monofumarate, present purification challenges U.S. Pat. No. 9,296,769, col. 5:1-5
• The Patented Solution: The patent claims a composition containing the TAF hemifumarate salt form while also specifying a level of purity with respect to a known impurity, tenofovir alafenamide monofumarate U.S. Pat. No. 9,296,769, abstract U.S. Pat. No. 9,296,769, col. 3:60-64 This invention provides not just the salt form itself, but a composition defined by its low level of a specific, process-related impurity.
• Technical Importance: By claiming a composition with a defined purity level, the patent protects a specific quality of the drug substance that possesses advantageous properties such as superior stability and reproducibility U.S. Pat. No. 9,296,769, col. 5:6-10

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶57
• The essential elements of Claim 1 are:
  • A composition comprising tenofovir alafenamide hemifumarate
  • wherein the composition comprises less than about 5% by weight of tenofovir alafenamide monofumarate

Multi-Patent Capsule: TAF Sesquifumarate Patent

• Patent Identification: U.S. Patent No. 9,777,028, “Co-Crystals, Salts and Solid Forms of Tenofovir Alafenamide,” issued October 3, 2017 Compl. ¶27
• Technology Synopsis: This patent discloses additional novel solid forms of TAF beyond the hemifumarate form. It specifically describes and claims tenofovir alafenamide sesquifumarate, which represents an alternative stable salt form for delivering the TAF prodrug U.S. Pat. No. 9,777,028, abstract U.S. Pat. No. 9,777,028, col. 2:26-31
• Asserted Claims: At least claim 7 Compl. ¶65
• Accused Features: The complaint alleges on information and belief that Cipla’s product will contain TAF sesquifumarate in addition to other fumarate forms Compl. ¶44

Multi-Patent Capsule: TAF Process Patents

• Patent Identification: U.S. Patent Nos. 8,664,386 (issued Mar. 4, 2014); 9,029,534 (issued May 12, 2015); 9,346,841 (issued May 24, 2016); and 9,676,804 (issued June 13, 2017), all titled “Methods for Preparing Anti-Viral Nucleotide Analogs” Compl. ¶¶28-31
• Technology Synopsis: These patents address the technical challenge that TAF is difficult to manufacture at commercially viable levels, in part due to the presence of three stereocenters Compl. ¶19 The patented solution is a novel synthetic route that substantially increases the yield of the desired TAF stereoisomer through a "crystallization-induced dynamic resolution," making the process commercially feasible Compl. ¶21 U.S. Pat. No. 8,664,386, col. 2:50-65
• Asserted Claims: At least claim 1 of each patent Compl. ¶¶73, 80, 87, 94
• Accused Features: The complaint alleges on information and belief that Cipla utilizes one or more of the claimed manufacturing processes to produce the TAF for its 505(b)(2) Products Compl. ¶45

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are "Cipla’s 505(b)(2) Products," which are identified as "emtricitabine/tenofovir alafenamide oral tablets in 120 mg/EQ 15 mg base and 200 mg/EQ 25 mg base strengths" Compl. ¶5

Functionality and Market Context

The accused products are oral tablets intended for the treatment of HIV-1 infection and for pre-exposure prophylaxis (PrEP) Compl. ¶46 The complaint alleges that Cipla's 505(b)(2) Application seeks approval for the same indications as Gilead's DESCOVY® and relies on Gilead's data to show bioequivalence (Compl. ¶¶35, 46). The central technical feature at issue is the specific solid form of tenofovir alafenamide (TAF) contained in the tablets. The complaint alleges, based on inference from Cipla's regulatory filings and other public information, that the product contains a "form of TAF fumarate" and will contain "multiple forms of TAF fumarate, including TAF monofumarate, TAF hemifumarate, and TAF sesquifumarate" (Compl. ¶¶40, 44).

IV. Analysis of Infringement Allegations

U.S. Patent No. 8,754,065 Infringement Allegations

U.S. Patent No. 9,296,769 Infringement Allegations

Identified Points of Contention

• Compositional Questions: A primary point of contention will be factual: what is the precise solid-state composition of the TAF active ingredient in Cipla's product? The complaint relies on "information and belief" and inferences drawn from Cipla’s Drug Master File listings for various TAF fumarates (Compl. ¶¶40, 42, 44). The litigation will likely focus on evidence from discovery to confirm or refute these allegations.
• Scope Questions: The complaint notes Cipla’s assertion in its notice letter that the TAF Hemi patents’ claims "clearly excludes other fumarates" Compl. ¶41 This raises the question of how the claims will be interpreted in the context of a mixture. A potential dispute is whether the presence of the claimed hemifumarate in a mixture with other forms (as alleged in Compl. ¶44) is sufficient for infringement, or if Cipla can argue its overall composition is a distinct, non-infringing form.

V. Key Claim Terms for Construction

The Term: "A composition comprising"

• Patent: ’769 Patent, Claim 1
• Context and Importance: The definition of this term is critical because the complaint alleges Cipla's product is a mixture of multiple TAF fumarate forms Compl. ¶44 Whether a mixture containing the claimed hemifumarate salt infringes will depend on whether the open-ended term "comprising" allows for the presence of other, unrecited TAF salt forms without defeating the claim.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: Practitioners may argue that "comprising" is a standard transitional phrase with a well-established, open-ended meaning, allowing the composition to include other components. The patent itself does not appear to provide an explicit definition that deviates from this standard interpretation.
  • Evidence for a Narrower Interpretation: A party might point to the specification's focus on the novel properties of the hemifumarate form in isolation, particularly its ability to purge other forms U.S. Pat. No. 9,296,769, col. 5:1-5, to argue that the invention is the substantially pure composition itself, not an arbitrary mixture containing it.

The Term: "hemifumarate"

• Patents: '065 Patent, Claim 1 and '769 Patent, Claim 1
• Context and Importance: This term defines the specific 2:1 stoichiometric ratio of TAF to fumaric acid. The case may turn on whether the material in Cipla's product meets this precise chemical definition. Given the allegation of a mixture of forms, a central question will be whether a distinct hemifumarate entity exists in the accused product.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The term itself has a clear chemical meaning. A party would argue that if testing reveals a crystalline phase consistent with the 2:1 ratio, that portion of the product infringes regardless of other phases present.
  • Evidence for a Narrower Interpretation: The patent defines the hemifumarate form by its unique properties and XRPD pattern U.S. Pat. No. 8,754,065, col. 2:44-51 A party could argue that if the accused mixture as a whole does not exhibit this characteristic pattern, it does not contain the claimed "hemifumarate" in the manner protected by the patent.

VI. Other Allegations

Indirect Infringement

The complaint alleges induced infringement for the TAF Hemi ('065 and '769) and TAF Sesqui (’028) patents. The factual basis is that Cipla's product label will allegedly instruct healthcare providers and patients to administer the drug for its approved indications, thereby causing direct infringement (Compl. ¶¶51, 59, 67). Knowledge is alleged based on Cipla's participation in the prior "TAF ANDA Litigation" for the TAF Hemi patents and on notice provided by Gilead post-receipt of the notice letter for the '028 patent (Compl. ¶¶51, 59, 67).

Willful Infringement

The complaint does not contain an explicit allegation of willful infringement.

VII. Analyst’s Conclusion: Key Questions for the Case

• A core issue will be one of compositional fact: What is the exact solid-state chemical identity of the tenofovir alafenamide in Cipla's proposed product? The case will likely depend heavily on analytical evidence from discovery to determine if the product contains, as Gilead alleges, the claimed hemifumarate and sesquifumarate forms, or if it consists of a different, non-infringing salt or mixture.
• A central legal question will be one of claim scope for mixtures: If Cipla’s product is found to be a mixture of various TAF fumarates, can a claim directed to "tenofovir alafenamide hemifumarate" be read to cover a product where the claimed salt is one of several components?
• For the four process patents, a key evidentiary question will be one of process tracing: What evidence can be developed to determine whether the manufacturing process Cipla uses in India to produce TAF incorporates the specific purification and resolution steps claimed by Gilead?